

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/K22A5CE6486EN.html>

Date: March 2020

Pages: 320

Price: US\$ 2,000.00 (Single User License)

ID: K22A5CE6486EN

Abstracts

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key

players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 17, 29, 7, 1, 38, 6 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Keratoconjunctivitis Sicca (Dry Eye) - Overview

Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development

Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment

Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics

Development

Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles

Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects

Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products

Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H1 2020

Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AB2 Bio Ltd

Abilita Bio Inc

Actinobac Biomed Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Allegro Ophthalmics LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allosterix Ltd

Allysta Pharmaceuticals Inc

Apidel SA

Ascendia Pharmaceuticals LLC

Aurinia Pharmaceuticals Inc

Aviara Pharmaceuticals Inc

AxeroVision Inc

Azura Ophthalmics Ltd

Bessor Pharma LLC

BRIM Biotechnology Inc

Cambium Medical Technologies LLC

Cellix Bio Pvt Ltd

Dhp Korea Ltd
Dompe Farmaceutici SpA
Emerald Bioscience Inc
EyGen Ltd
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
HanAll Biopharma Co Ltd
Huons Co Ltd
Huons Global Co Ltd
Icure Pharmaceutical Inc
Ipsen SA
IVIEW Therapeutics Inc
Kala Pharmaceuticals Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kv1.3 Therapeutics
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
LTT Bio-Pharma Co Ltd
Lubris Biopharma
Marinomed Biotech AG
MC2 Therapeutics AS
Merck & Co Inc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
Nanomerics Ltd
Neuroptika Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
Ocunova LLC
OKYO Pharma Ltd

OncoNOx ApS
Oyster Point Pharma Inc
Palatin Technologies Inc
Panag Pharma Inc
Panoptes Pharma GesmbH
Pharmaleads SA
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
RHNanopharmaceuticals LLC
RiniSight Inc
Samjin Pharm Co Ltd
Senju Pharmaceutical Co Ltd
Serentrix LLC
Silk Technologies Ltd
Stuart Therapeutics Inc
Surface Pharmaceuticals Inc
Sylentis SAU
Tarsius Pharma Ltd
TearSolutions LLC
Tetra Bio-Pharma Inc
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA
Yuyu Pharma Inc

I would like to order

Product name: Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/K22A5CE6486EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K22A5CE6486EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970